Browse the corpus

Felbamate is an anti-epileptic drug that the Food and Drug Administration approved for the management of focal seizures and Lennox-Gastaut syndrome. It should be a consideration for patients with drug-resistant epilepsy where the benefit of seizure control outweighs the risk of severe idiosyncratic reactions. This activity focuses on the indications, mechanism of action, methods of administration, significant adverse effects, and contraindications. Additionally, this CME reviews the monitoring and toxicity of felbamate. Understanding the complex pharmacology of felbamate enables healthcare professionals to tailor treatments for a patient-centered approach. This continuing medical education (CME) activity is designed to provide essential knowledge and practical tools for the optimal administration of felbamate. This educational initiative highlights the significant role of the interprofessional healthcare team in managing felbamate therapy. The CME program aims to provide evidence-based medicine to improve patient care and outcomes. It focuses on strategies to minimize adverse reactions while maximizing the effectiveness of lidocaine. This training will equip healthcare professionals with the knowledge to deliver safe, effective, and individualized care during felbamate administration. Objectives: Evaluate the mechanism of action of felbamate in epilepsy. Identify the FDA-approved indications of felbamate. Assess the potential adverse events associated with felbamate therapy. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from felbamate therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Acute Overdose Felbamate overdose may cause central nervous system depression, altered mental status, ataxia, vomiting, and crystalluria, which may lead to acute kidney injury (AKI). Crystals may be visible on urinalysis and primarily contain unchanged felbamate and its metabolites. A 20-year-old woman presented with altered mental status, extensive crystalluria, unilateral hydronephrosis, and AKI after intentionally ingesting felbamate with sodium valproate. In another case, a 3-year-old child developed vomiting, ataxia, hematuria, and needle-like urinary crystals after accidental overdose of felbamate. Management of Overdose There is no antidote for felbamate. The initial management includes stabilization of airway, breathing, and circulation. Endotracheal intubation may be required in patients with markedly altered mental status.[28] Supportive treatment with intravenous fluids enhances renal clearance of felbamate, especially when crystalluria or AKI is present. Urine microscopy and renal ultrasound may help identify nephrotoxic effects. In both reported cases, crystalluria and AKI resolved following parenteral hydration, and both patients made a complete recovery.[29][30]

Felbamate therapy is most effectively implemented through an interprofessional healthcare team that includes clinicians, specialists, nurses, and pharmacists. Monitoring for idiosyncratic reactions to felbamate falls under the responsibility of neurologists and primary care physicians. The pharmacist should thoroughly educate the patient and caregiver about the importance of medication adherence and the need for regular follow-up.[31] Advanced practice providers (APPs) play a critical role in monitoring for early signs of hematologic or hepatic adverse effects during felbamate therapy. They should collaborate closely with the care team to ensure timely evaluation and intervention when concerns arise. Close monitoring is vital because the drug has correlations with severe adverse reactions; this requires interprofessional communication between the specialties to ensure no issues arise. Nursing is often the first point of contact the patient has with the healthcare team. They need to be prepared to offer counsel, answer questions, and alert appropriate team members if intervention is warranted. As noted above, clinical and laboratory monitoring is essential following drug initiation, though it may be spaced out after the first 3 months of therapy. If there is a concern for aplastic anemia or hepatic dysfunction in any patients on felbamate, they should be evaluated in an emergency care setting. An interprofessional team approach and effective communication among primary care physicians, neurologists, advanced practice providers, pharmacists, and nurses are crucial for decreasing potential adverse effects, such as hepatoxicity and aplastic anemia, and improving patient outcomes related to felbamate therapy.